Boehringer Ingelheim to present Pradaxa data at AHA event

Boehringer Ingelheim will be attending the upcoming scientific sessions of the American Heart Association, where it will share the latest efficacy and safety data for Pradaxa (dabigatran etexilate).

Data from eight presentations sponsored by Boehringer Ingelheim will be included in the scientific programme and will add to the growing body of evidence on the clinical benefits of the novel oral anticoagulant.

These will include the first results from a healthy volunteer study of a dabigatran-specific antidote and unique outcome findings from over six years of follow-up data from the pivotal phase III RE-LY trial and its extension study RELY-ABLE.

Pradaxa is the only novel oral anticoagulant to be supported by this amount of long-term clinical evidence.

Professor Klaus Dugi, corporate senior vice-president for medicine at Boehringer Ingelheim, said: "The American Heart Association's scientific sessions provide a vital forum for physicians to share the most recent clinical developments in the field of cardiology."

Last month, the company reported new study data showing how Pradaxa can deliver better outcomes than warfarin in cases where major bleeding occurs.